Financial Performance - Revenues for Q1 2025 were $114,802,000, representing a 40.2% increase from $81,875,000 in Q1 2024[16] - Gross profit for Q1 2025 was $61,097,000, up 56.3% from $39,108,000 in Q1 2024[16] - Net income for Q1 2025 was $26,904,000, compared to $17,806,000 in Q1 2024, marking a 51.1% increase[16] - Basic earnings per share for Q1 2025 were $0.11, up from $0.08 in Q1 2024[16] - Adjusted EBITDA for Q1 2025 was $47.9 million, an increase of $21.5 million compared to $26.4 million in Q1 2024[125] - The income before taxes for the three months ended March 31, 2025, was $33.5 million, compared to $18.4 million for the same period in 2024, representing an increase of 81.5%[83] - The effective tax rate for the three months ended March 31, 2025, was 19.6%, significantly higher than the 3.2% effective tax rate for the same period in 2024[83] - The company achieved net income of $26.9 million for the three months ended March 31, 2025, compared to $17.8 million in the same period in 2024[140] - The company achieved a net income of $197.7 million for the year ended December 31, 2024, marking its first GAAP net income in history, with positive cash flow from operations of $118.7 million[96] Assets and Liabilities - Total current assets increased to $351,814,000 as of March 31, 2025, from $331,410,000 at the end of 2024[14] - Total stockholders' equity rose to $373,419,000 as of March 31, 2025, compared to $349,018,000 at the end of 2024[14] - Total assets of the Company as of March 31, 2025, were $510.6 million, up from $350.9 million as of March 31, 2024, indicating a growth of 45.5%[75] - As of March 31, 2025, total accrued expenses and other current liabilities were $31.6 million, a decrease from $34.0 million at December 31, 2024[48] - The Company has lease liabilities of $9.5 million as of March 31, 2025, with scheduled payments totaling $14.2 million over the remaining lease terms[81] - The Company has a total of $72.5 million in senior notes payable, with a term loan and revolving credit facility both fully drawn as of March 31, 2025[49] - As of March 31, 2025, the outstanding balance on the revolving credit facility was $42.5 million, and the term loan facility was $32.5 million[133] Cash Flow and Expenses - The company reported a net cash used in operating activities of $19,675,000 for Q1 2025, compared to $2,218,000 in Q1 2024[20] - Net cash used in operating activities for the three months ended March 31, 2025, was $19.7 million, an increase of $17.5 million from the same period in 2024[140] - Net cash used in investing activities increased to $4.7 million for the three months ended March 31, 2025, primarily due to a $1.3 million roof replacement at the Boca Facility[141] - Net cash used in financing activities was $7.1 million for the three months ended March 31, 2025, compared to $1.4 million in 2024[142] - The Company incurred research and development expenses of $0.8 million for the three months ended March 31, 2025, compared to $0.5 million for the same period in 2024, reflecting a 83.5% increase[73] - Selling, general and administrative expenses rose to $24.1 million in Q1 2025, an increase of $8.4 million from Q1 2024, with SG&A as a percentage of net revenues increasing from 19.1% to 21.0%[119] Customer Concentration - For the three months ended March 31, 2025, three customers represented approximately 74% of the company's consolidated revenues, compared to two customers representing 70% for the same period in 2024[38] - As of March 31, 2025, accounts receivable included allowances for customer credits and credit losses amounting to $3.0 million, with three customers accounting for approximately 85% of total accounts receivable[29] - For the three months ended March 31, 2025, two customers represented approximately 64% of consolidated revenues, compared to 70% for the same period in 2024[192] - The company anticipates increased revenue from key customers over the next few years, but any adverse change in their financial condition could negatively affect revenue[194] Regulatory and Compliance - The company is currently evaluating the impact of recent accounting pronouncements on its consolidated financial statements, including ASU 2023-09 and ASU 2024-03[42][43] - The FDA approved the Company's Prior Approval Supplement for its yield enhancement production process in April 2025, expected to increase production yields of ASCENIV and BIVIGAM by approximately 20%[85][97] - The FDA approved the expansion of BIVIGAM's label to include pediatric patients aged two years and older in December 2023[105] - The Company plans to file a supplemental Biologics License Application for ASCENIV's label expansion to include pediatric patients in mid-2025, with potential FDA approval in the first half of 2026[101] - The company is subject to periodic inspections by the FDA, which could result in regulatory actions that may materially impact operations[168] Risks and Challenges - The company faces risks from geopolitical and economic conditions, including potential disruptions to the supply chain due to international conflicts and trade policies[167] - The company may not be able to accurately forecast revenue due to uncertainties in market opportunity estimates and growth forecasts[165] - The company faces significant costs and time delays in obtaining regulatory approval for product candidates, which may impact business operations[173] - The company may not be able to generate revenue from product candidates if regulatory approvals are not obtained, limiting revenue sources to plasma collection and sales[182] - The company relies on third-party contractors for filling, packaging, testing, and labeling, which poses risks of delays and quality issues that could adversely affect commercialization efforts[160] - The company is subject to numerous environmental, health, and safety laws, which could result in substantial fines or penalties if compliance is not maintained[171] Operational Developments - The company continues to focus on developing a pipeline of plasma-derived therapeutics for immunocompromised patients[21] - The Company entered into an Amended and Restated Plasma Purchase Agreement with Grifols, requiring a minimum supply of 35,000 liters of RSV plasma annually[66] - The Company is currently focused on expanding its manufacturing capacity and product output capability at its Boca Facility, which may lead to supply shortages during the validation process[189] - The Company operates ten FDA-licensed plasma collection facilities, capable of collecting approximately 30,000 to 50,000 liters of source plasma annually per facility[94] Market and Competitive Landscape - The company faces intense competition in the biotechnology and pharmaceutical industries, with competitors having greater financial resources and R&D capabilities[207] - The acceptance and use of the company’s products by physicians, payers, and patients are critical for revenue generation, influenced by safety perceptions and cost-effectiveness[199] - The market exclusivity of products is critical, as significant revenue declines can occur once exclusivity expires and generics are introduced[209] Stock and Financing - In May 2025, the Board of Directors authorized a share repurchase program of up to $500 million of the Company's outstanding shares[86] - The Company entered into a senior secured credit facility with Ares Capital Corporation, providing a total of $135.0 million in credit facilities, fully drawn on December 18, 2023[132] - On May 5, 2025, the company borrowed $30 million under the revolving credit facility and repaid an additional $30 million against the term loan[206]

Financial Performance - 1Q 2025 total revenue reached $114.8 million, a 40% year-over-year increase from $81.9 million in 1Q 2024[1][7] - Adjusted total revenue for 1Q 2025 was $118.6 million, representing approximately 45% year-over-year growth when excluding one-time product withdrawals[1][7] - GAAP net income for 1Q 2025 was $26.9 million, a 51% increase compared to $17.8 million in 1Q 2024[1][9] - Adjusted EBITDA for 1Q 2025 was $47.9 million, reflecting an 81% year-over-year growth from $26.4 million in 1Q 2024[1][10] - Total revenue for Q1 2025 was $114.8 million, a 40.2% increase from $81.9 million in Q1 2024[21] - Gross profit for Q1 2025 was $61.1 million, compared to $39.1 million in Q1 2024, reflecting a significant improvement in profitability[21] - Adjusted revenues for Q1 2025, including customer credits related to the Voluntary Withdrawal, were $118.6 million[22] - Net income for Q1 2025 was $26.9 million, up from $17.8 million in Q1 2024, representing a 51.5% year-over-year increase[21] - Adjusted EBITDA for Q1 2025 was $47.9 million, compared to $26.4 million in Q1 2024, indicating strong operational performance[24] - The company reported a basic earnings per share of $0.11 for Q1 2025, up from $0.08 in Q1 2024[21] Guidance and Projections - FY 2025 total revenue guidance increased to more than $500 million, with FY 2026 guidance raised to over $625 million[2][5] - FY 2025 adjusted net income guidance reaffirmed at $175 million or more, while FY 2026 adjusted net income guidance increased to $245 million[2][5] - Anticipated total annual revenues prior to 2030 are now projected to exceed $1.1 billion, with expected outsized earnings growth[2][5] Cash and Assets - Total cash and receivables grew to approximately $171 million by the end of 1Q 2025[1][4] - Cash and cash equivalents decreased to $71.6 million as of March 31, 2025, from $103.1 million at the end of 2024[19] - Total assets increased to $510.6 million as of March 31, 2025, compared to $488.7 million at the end of 2024[19] Shareholder Actions - The company authorized a $500 million share repurchase program, representing approximately 8% of its current market capitalization[2][4] Operational Enhancements - The FDA approved a yield enhancement process expected to increase production output by 20% from the same starting plasma volume[2][4] - The company plans to further pay down its outstanding debt, with senior notes payable at $72.5 million[19] - The company is focused on expanding its plasma supply agreements to enhance ASCENIV's growth and financial performance[21]

Core Insights - ADMA Biologics reported a strong financial performance in Q1 2025, with total revenue of $114.8 million, representing a 40% year-over-year increase, and adjusted total revenue of $118.6 million, indicating approximately 45% growth when excluding one-time product withdrawals [1][9] - The company achieved a GAAP net income of $26.9 million, a 51% increase year-over-year, and an adjusted net income of $33.3 million, reflecting an 87% year-over-year growth [1][11] - Adjusted EBITDA for the quarter was $47.9 million, marking an 81% increase compared to the same period last year [1][12] Financial Performance - Total cash and receivables grew to approximately $171 million, providing a strong liquidity position [1][3] - The gross profit for Q1 2025 was $61.1 million, translating to a gross margin of 53.2%, up from 47.8% in Q1 2024 [10] - The company has increased its total revenue guidance for FY 2025 to more than $500 million and for FY 2026 to more than $625 million [1][7] Strategic Developments - The FDA approved a yield enhancement production process, expected to increase production output by 20% from the same starting plasma volume, which is anticipated to support revenue growth and margin expansion [1][3] - ADMA has authorized a $500 million share repurchase program, representing approximately 8% of its current market capitalization, aimed at enhancing stockholder value [1][8] - A debt reorganization has reduced ADMA's cost of debt capital by 1.1%, further strengthening its financial position [1][3] Market Position and Outlook - The company expects total annual revenues to exceed $1.1 billion by 2030, with significant earnings growth anticipated from current margin levels [2][7] - ADMA's U.S.-based manufacturing and supply chain provide insulation from geopolitical and global trade challenges, positioning the company favorably against multinational competitors [3][7] - The demand for ASCENIV, one of ADMA's key products, continues to trend towards record highs, with expectations for increased market penetration and new patient starts [4][7]

Core Viewpoint - Despite major market indexes like the S&P 500 struggling in 2025, certain mid-cap stocks in the medical and biotechnology sectors are showing strong performance and growth potential, presenting investment opportunities for those looking beyond large-cap stocks [1]. Group 1: Penumbra - Penumbra, Inc. is a high-growth medical devices company with a market capitalization of $11.3 billion, focusing on neuro and vascular interventions [2][3]. - The stock has increased by 23% year-to-date and 43% over the past 12 months, demonstrating resilience amid broader market volatility [2][3]. - The company reported Q1 earnings of $0.83 per share, exceeding estimates by $0.17, with revenue rising 16.3% year-over-year to $324.1 million [3]. - Analysts maintain a Moderate Buy consensus rating, with a price target of $302.40, indicating further upside potential [4]. Group 2: TransMedics Group - TransMedics Group is a commercial-stage medical technology company focused on organ transplant procedures, with a market cap of $92.18 million [6]. - The stock has surged nearly 48% year-to-date, following a breakout above key resistance levels [7]. - Analysts have a Moderate Buy consensus rating, with a price target of $124.20, suggesting up to 35% upside from current levels [8]. Group 3: ADMA Biologics - ADMA Biologics is a biopharmaceutical company specializing in plasma-derived biologics, with a market capitalization of $5.6 billion [10]. - The stock has risen 38% year-to-date and is trading just 7% below its all-time high [10][11]. - The company has a P/E ratio of 29 and a forward P/E of 23, with projected EPS growth of 45% in 2025, supported by a Buy rating from all four analysts covering the stock [11].

Market Overview - The three major U.S. indexes (Nasdaq Composite, S&P 500, Dow Jones Industrial Average) ended the past trading week positively, with gains of 3.52%, 2.86%, and 3.41% respectively [1] - Despite a gloomy economic outlook due to shifts in U.S. foreign tariff policy, weak economic data, and rising geopolitical tensions, investors are optimistic about strong earnings results and potential reductions in import duties by the Trump administration [1] Economic Indicators - The U.S. GDP contracted for the first time in three years, growing at an annualized rate of 0.3% in Q1 2025, down from 2.4% in the previous quarter [2] - Consumer sentiment index dropped to 52.2 in April from 57.0 in March, marking the lowest level since July 2022 [2] - The consumer confidence index fell to 86 in April from 92.9 in March [2] - The Personal Consumption Expenditure (PCE) index remained flat in March, while personal consumption and personal income grew by 0.7% and 0.5% respectively, exceeding expectations [2] Manufacturing and Labor Market - The manufacturing PMI for April contracted to 48.7% from 49% in March, indicating contraction in manufacturing activities [3] - Nonfarm payrolls increased by 177,000 in April, exceeding analyst expectations, while the unemployment rate remained unchanged at 4.2% [3] Stock Performance and Recommendations - ADMA Biologics, Inc. shares gained 48.6% since being upgraded to Zacks Rank 2 (Buy) on March 4, outperforming the S&P 500's 3% decrease [4] - Intrepid Potash, Inc. shares returned 28.9% since its upgrade to Zacks Rank 2 on March 6, also outperforming the S&P 500 [5] - The Zacks Model Portfolio of Rank 1 stocks has outperformed the S&P 500 index by almost 13 percentage points since 1988, with an annualized average return of +23.9% [7] Focus List and Portfolios - Constellation Brands, Inc. gained 8.2% over the past 12 weeks, while Cheniere Energy, Inc. returned 2.3% during the same period [11] - The Zacks Focus List portfolio returned -2.96% in Q1 2025, compared to -4.30% for the S&P 500 index [12] - The Zacks Earnings Certain Admiral Portfolio (ECAP) returned +3.20% in Q1 2025, outperforming the S&P 500 index's -4.30% decline [16] Dividend and Defensive Stocks - Coca-Cola Company returned 13.5% over the past 12 weeks, while Quest Diagnostics Incorporated increased by 7.9% [18] - The Zacks Earnings Certain Dividend Portfolio (ECDP) returned +5.74% in Q1 2025, outperforming the S&P 500 index's -2.41% pullback [19] Top 10 Stocks Performance - Primo Brands Corporation increased by 7.4% year-to-date, compared to the S&P 500 index's 3.3% decrease [22] - The Top 10 portfolio returned +62.98% in 2024, significantly outperforming the S&P 500 index's +25.04% return [22][23]

Group 1 - Adma Biologics closed at $23.52, with a +1.07% change, underperforming the S&P 500's daily gain of 1.47% [1] - Over the past month, shares of Adma Biologics gained 19.64%, outperforming the Medical sector's loss of 2.95% and the S&P 500's loss of 0.47% [1] Group 2 - The upcoming earnings release on May 7, 2025, is expected to show an EPS of $0.16, a 100% increase from the same quarter last year, with projected net sales of $119.1 million, up 45.46% year-over-year [2] - For the full year, analysts expect earnings of $0.71 per share and revenue of $495.8 million, reflecting changes of +44.9% and +16.26% respectively from the previous year [3] Group 3 - Changes in analyst estimates for Adma Biologics are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), indicates that Adma Biologics currently holds a Zacks Rank of 2 (Buy) [6] Group 4 - Adma Biologics has a Forward P/E ratio of 32.78, which is a premium compared to the industry average Forward P/E of 17.32 [7] - The Medical - Biomedical and Genetics industry, which includes Adma Biologics, holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [7]

Core Viewpoint - ADMA Biologics is expected to report first-quarter 2025 results on May 7, with sales estimated at $119.1 million and earnings at 16 cents per share, reflecting a positive trend in earnings estimates for 2025 and 2026 [1][2][16]. Financial Performance - The earnings estimate for 2025 has increased to 71 cents from 69 cents per share over the past 60 days, while the estimate for 2026 has improved to 93 cents from 87 cents [1][2]. - ADMA has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 32.8%, although it missed estimates by 6.67% in the most recent quarter [2][3]. Product Overview - ADMA markets plasma-derived biologics, including three FDA-approved products: Bivigam, Asceniv, and Nabi-HB, aimed at treating immune deficiencies and preventing infectious diseases [6][17]. - Asceniv, the lead product, is a plasma-derived IVIG that contains polyclonal antibodies to neutralize microbes and prevent infections [7][8]. Sales and Growth Drivers - Increased sales of Asceniv are expected to drive revenue growth in the first quarter, supported by a favorable mix of high-margin immunoglobulin sales [9]. - ADMA anticipates significant growth in revenues, projecting over $490 million in 2025 and $605 million in 2026, with net income expected to exceed $175 million in 2025 [16]. Market Position and Strategy - ADMA has entered into long-term high-titer plasma supply contracts, increasing access to raw materials and potentially achieving $1 billion in annual revenues by 2030 [14]. - The company competes with Takeda and Grifols in the U.S. plasma-derived products market and is positioned for substantial growth in the underserved immune-compromised patient population [17][18]. Valuation - ADMA's shares currently trade at a price/sales ratio of 10.59x forward sales, significantly higher than its historical mean of 3.32x and the industry average of 1.76x, indicating a premium valuation [12]. Price Performance - ADMA's stock has surged 38.8% year-to-date, outperforming the industry, which has declined by 2.7% [10].

Group 1 - Adma Biologics (ADMA) has shown a year-to-date return of 38.8%, significantly outperforming the average return of -1.2% for the Medical sector [4] - The Zacks Consensus Estimate for ADMA's full-year earnings has increased by 3.7% over the past three months, indicating improved analyst sentiment and earnings outlook [4] - Adma Biologics is ranked 2 (Buy) in the Zacks Rank system, which highlights stocks with characteristics likely to outperform the market in the near term [3] Group 2 - Adma Biologics is part of the Medical - Biomedical and Genetics industry, which has an average return of -1.8% this year, further showcasing ADMA's strong performance relative to its peers [6] - Another notable stock in the Medical sector is Agilon Health (AGL), which has returned 124.2% year-to-date and also holds a Zacks Rank of 2 (Buy) [5] - The Medical Services industry, to which Agilon Health belongs, has a current ranking of 68 and has experienced a return of -0.8% this year [6]

Adma Biologics (ADMA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this infectious disease drug developer have returned +17.7% over the past month versus the Zacks S&P 500 composite's -0.7% change. The Zacks Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has lost 1.6% over this period. Now the key question is: Where could ...

Market Overview - Wall Street has experienced significant volatility in 2025, with all three major stock indexes (Dow, S&P 500, Nasdaq Composite) in negative territory year to date [1] - Small-cap benchmarks (Russell 2000, S&P 600) and mid-cap-specific S&P 400 Index are also in the red year to date [1] High-Performing Mid-Cap Stocks - Despite market headwinds, five mid-cap stocks have provided over 25% returns year to date: ADMA Biologics Inc. (ADMA), FirstCash Holdings Inc. (FCFS), Stride Inc. (LRN), Life Time Group Holdings Inc. (LTH), and National Fuel Gas Co. (NFG) [2] - These stocks exhibit strong revenue and earnings growth potential for 2025, with positive earnings estimate revisions over the last 60 days [3] ADMA Biologics Inc. - ADMA Biologics specializes in plasma-based biologics for treating and preventing infectious diseases, targeting immune-compromised individuals [7][8] - Expected revenue growth rate is 16.3% and earnings growth rate is 44.9% for the current year, with a 2.9% improvement in earnings estimates over the last 60 days [9] FirstCash Holdings Inc. - FirstCash operates retail pawn stores across the U.S., Mexico, and Latin America, providing loans against personal property and retailing forfeited merchandise [10][11] - Expected revenue growth rate is 0.2% and earnings growth rate is 17.2% for the current year, with a 2.6% improvement in earnings estimates over the last seven days [13] Stride Inc. - Stride is a technology-based education service company offering online curriculum and educational services [14] - Expected revenue growth rate is 14.9% and earnings growth rate is 48.4% for the current year, with a 4.3% improvement in earnings estimates over the last 30 days [16] Life Time Group Holdings Inc. - Life Time provides health, fitness, and wellness experiences, operating various fitness and recreation centers [17][18] - Expected revenue growth rate is 12.9% and earnings growth rate is 37.9% for the current year, with a 6.5% improvement in earnings estimates over the last 60 days [19] National Fuel Gas Co. - National Fuel Gas focuses on systematic investments to strengthen operations and reduce emissions, with significant capital investments planned [20][21] - Expected revenue growth rate is 31.5% and earnings growth rate is 39.1% for the current year, with a 1.9% improvement in earnings estimates over the last 60 days [22][23]